SMi Group's Pain Therapeutics returns for its 14th year next may in London

1. REGISTER BY 28TH FEBRUARY AND RECEIVE A £300 DISCOUNT
REGISTER BY 31ST MARCH AND RECEIVE A £100 DISCOUNT
SMi present the 14th Annual Conference on…
PAIN THERAPEUTICS
Assess Alternative Approaches to Animal Models to Minimise
the Translational Gap and Accelerate Market Access
19TH - 20TH
MAY
2014
Holiday Inn Regents Park Hotel, London, UK
CONFERENCE CHAIRS FOR 2014:
• Jordi Serra, Chief Scientific
Officer, Neuroscience
Technologies Ltd
• Dr Kathleen Kelly, Medical
Leader, Janssen
Pharmaceutical Research
& Development L.L.C.
KEY SPEAKERS INCLUDE:
• Samer Eid, Director,
Neuroscience Scientific
Knowledge Discovery,
Merck
• Tom McCarthy, CEO,
Spinifex
• Zara Sands, Principal
Scientist, Computational
Medicinal Chemist, UCB
• Birgit Priest, Research
Advisor, Eli Lilly
• Philip R Kym, Director of
Chemistry, Centralised Lead,
Optimisation, AbbVie
• Stephen Wright, R&D
Director, GW
Pharmaceuticals
BUSINESS BENEFITS FOR 2014:
• Discuss and evaluate the latest new therapeutic mechanisms
from bench to bedside with key insight from Merck, Spinifiex, Eli
Lilly, AbbVie and UCB
• Hear key presentations from Mundipharma Research and Nektar
on advances to opioids and strategies to reduce abuse potential
• Explore the latest in the area of Neuropathic pain for 2014 with
the latest case studies from Neuroscience Technologies and GW
Pharmaceuticals
• Evaluate the translation gap with case studies from a pre-clinical
and clinical perspective from Karolinska Institutet and
OGBConsulting
PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Wednesday 21st May 2014, Holiday Inn Regents Park Hotel, London, UK
A: How Can Success in Analgesia be Improved?
B: Opportunities for Collaborative Pain Projects
Workshop Leaders: Steve Harrison, Vice President, Research Biology,
Nektar Pharmaceuticals
Birgit Priest, Research Advisor, Eli Lilly
8.30am - 12.30pm
Workshop Leader: Fiona Boissonade, Head of Neuroscience,
University of Sheffield
1.30pm - 5.30pm
www.pain-therapeutics.co.uk
BOOK BY 28TH FEBRUARY AND SAVE £300 / BOOK BY 31ST MARCH AND SAVE £100
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

2. Pain Therapeutics
www.pain-ther
Day One | Monday 19th May 2014
8.30
Registration & Coffee
12.50
Networking Lunch
9.00
Chairman's Opening Remarks
Dr Kathleen Kelly, Medical Leader, Janssen Pharmaceutical
Research & Development L.L.C.
1.50
How do we produce a step change in the discovery of new
analgesics?
• Epigenetic proteins are fundamental mediators of chronic
pain pathology
• In early discovery, more open partnerships between
academia and industry are critical
• In vitro clinical assays are likely more predictive of activity
in patients
Chas Bountra, Chief Scientist (SGC), Professor of Translational
Medicine, University of Oxford
2.30
Highlights from AbbVie pain research: TRPV1, TrkA, Cav2.2,
and Nav1.7
• The discovery of modality specific TRPV1 antagonists that
demonstrate reduced liabilities with respect to core body
temperature increase and the loss of sensation of noxious
heat
• The discovery of Cav2.2 and Nav1.7 clinical candidates
for the treatment of chronic pain
• The discovery of TrkA inhibitors for the treatment of chronic
pain
Philip R Kym, Director of Chemistry, Centralised Lead
Optimisation, AbbVie
3.10
Afternoon Tea
ASSESSING NEW MECHANISMS - BENCH TO BEDSIDE
PART
ONE
9.10
9.50
10.30
11.00
OPENING ADDRESS
Accelerating innovation in research to build
the pain pipeline
• Filling the pain clinical development pipeline
• Open innovation in pain research
• Novel targets/mechanisms and new directions in pain
research
Samer Eid, Director, Neuroscience Scientific Knowledge
Discovery, Merck
How can in silico approaches be used to prospectively drive
membrane protein drug discovery programs?
• Importance of establishing expectations and aligning
resources accordingly
• Examples of effective applications of computational
approaches for driving drug design cycles
• Potential pit falls and future prospects
Zara Sands, Principal Scientist, Computational Medicinal
Chemist, UCB
Morning Coffee
ENHANCING THE TRANSLATION OF ANIMAL DATA INTO PAIN PATIENTS
KEYNOTE PRESENTATION
Mechanistic studies supporting the angiotensin II type
2 receptor antagonist MOA in chronic pain through to
presentation of Phase 2 efficacy and safety data
• Efficacy and safety data from Phase 2 clinical trial of EMA401
in postherpetic neuralgia.
• Mechanism of action studies in human sensory neurons and
clinical tissues.
• Update on ongoing clinical trials of EMA401.
Tom McCarthy, CEO, Spinifex
Praveen Anand, Professor of Clinical Neurology, Lead Clinician
for Pain Services, Imperial College Healthcare NHS Trust
3.40
The translational gap and assessing failures case study 1:
pre-clinical perspective
• Experimental models versus clinical trials
• Translation from animal models to man
• Failed pain mechanisms?
Professor Odd-Geir Berge, Independent Consultant,
OGBConsulting
4.20
The translational gap and assessing failures case study 2:
clinical perspective
• Translation from a clinical perspective
• Human proof of concept
• Failed mechanisms or failed studies?
Jarkko Kalliomaki, MD, PhD, Clinical Pain Research, Dept of
Molecular Medicine and Surgery, Karolinska Institutet
5.00
Chairman's Closing Remarks and Close of Day One
Q&A Session
12.20
Round Table Discussion:
Should animal models only be used for PK/PD
testing for exposure of the compound?
ROUND
TABLE
DISCUSSION
Register online at: www.pain-therapeutics.co.uk • Alternatively fax
Who should attend:
Heads of Department, Directors, Managers,
Team Leaders Researchers and Scientists from:
• Clinical Trials
• Neuroscience
• Translational Medicine/R&D
• Pain and inflammation target discovery
• Analgesic preclinical development
• CNS clinical trials
• Translational imaging
• Early phase CNS research
• Epigenetics in pain and inflammation
• Chronic and neuropathic pain
• Clinical trial design
• Pain Management
SPONSORSHIP AND EXHIBITION
OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored to
complement your company’s marketing
strategy. Prime networking opportunities exist
to entertain, enhance and expand your client
base within the context of an independent
discussion specific to your industry.
Should you wish to join the increasing number
of companies benefiting from sponsoring our
conferences please call:
Alia Malick on +44 (0) 20 7827 6168
or email: amalick@smi-online.co.uk
Want to know how you can
get involved?
Interested in promoting your
services to this market?
Contact Teri Arri, SMi Marketing on
+44 (0) 207 827 6162, or email:
tarri@smionline.co.uk

3. apeutics.co.uk
8.30
Registration & Coffee
9.00
Chairman's Opening Remarks
Jordi Serra, Chief Scientific Officer, Neuroscience
Technologies Ltd
Day Two | Tuesday 20th May 2014
ASSESSING NEW MECHANISMS - BENCH TO BEDSIDE
PART
1.20
New Tools in the Translation from Bench to Clinic
TWO
• Failure of recent developmental compounds
to demonstrate analgesic efficacy in the clinic
• Possible explanations based on divergent pharmacology
• New tools and approaches to better predict human
pharmacology and efficacy
Birgit Priest, Research Advisor, Eli Lilly
2.00
Overview of Fulranumab Clinical Development
• Nerve Growth factor (NGF) is elevated in tissues in
response to injury and inflammation
• Antibody inhibitors of NGF have shown efficacy in treating
pain
• Fulranumab is a fully human monoclonal antibody inhibitor
of NGF in development
• Phase 2 efficacy and safety data for fulranumab will be
presented
Dr Kathleen Kelly, Medical Leader, Janssen Pharmaceutical
Research & Development L.L.C.
2.40
Afternoon Tea
ADVANCES IN OPIOIDS
9.10
9.50
Opioids and the treatment of Chronic Pain
• The old and the new formulation of OxyContin – what is it
all about or what is the difference?
• Reviewing novel formulation strategies to reduce opioid
abuse
• Analysing the recent advances to opioids – moving
forward
Alexander Oksche, Executive Director of Pharmacological
Intelligence, Mundipharma Research
SPOTLIGHT PRESENTATION
Novel Opioid Therapeutics with Intrinsically Reduced Abuse
Potential
• NKTR-181, a slow brain entry opioid for Chronic Pain
• Opioid therapeutics with novel pharmacology for the
treatment of acute pain
Steve Harrison, Vice President, Research Biology, Nektar
Pharmaceuticals
10.30
Morning Coffee
11.00
Zero Tolerance for Chronic Pain Growth factor signaling
selectively mediates tolerance to morphine
• Growth factor inhibition eliminates or reverses morphine
tolerance.
• Newly discovered relationships between opioid tolerance
and neuropathic pain suggests that this class of drugs
could become important therapeutic targets for pain
treatment.
Howard B. Gutstein, MD, Professor, Departments of
Anesthesiology and Biochemistry/Molecular Biology MD
Anderson Cancer Center, Founder, Morpheus
Pharmaceuticals
11.40
12.20
NEUROPATHIC PAIN
3.10
Microneurography as a method for recording individual
action potentials from nociceptors and its value in drug
development in neuropathic pain.
• Analysing analgesic efficacy in preclinical animal models
• Reviewing proof-of-concept studies that allow critical
testing of presumed mechanism of action
• Recording individual action potentials from single sensory
fibres, including nociceptors to detect and quantify
abnormal activity in human pain fibres
Jordi Serra, Chief Scientific Officer, Neuroscience
Technologies Ltd
3.50
Cannabinoids in neuropathic pain: What have we learnt?
• Responses to cannabinoids across different neuropathic
pain types
• The importance of non-psychoactive cannabinoids
• Cannabinoid modulation of neurotransmission vs
inflammation
Stephen Wright, R&D Director, GW Pharmaceuticals
Discussion Panel: Strategies for reduced
PANEL
abuse potential
DEBATE
• Insights into the future of opioids
• Assessing alternatives to opioid therapeutics
• Evaluating how to move forward to minimise
opioid misuse
Steve Harrison, Vice President, Research Biology, Nektar
Pharmaceuticals
Alexander Oskche, Executive Director of Pharmacological
Intelligence, Mundipharma Research
Howard B. Gutstein, MD, Professor, Departments of
Anesthesiology and Biochemistry/Molecular Biology MD
Anderson Cancer Center, Founder, Morpheus
Pharmaceuticals
4.30 Advances into new therapeutic strategies for pain reduction
• Assessing the correlation between molecular targets and
the degree of pain
• Reviewing molecule-to-man studies combining molecular
genetics, molecular biology, and biophysics
• Demonstrating the contribution of ion channels to human
pain and the importance for axonal conduction
Fiona Boissonade, Head of Neuroscience, University of
Sheffield
Networking Lunch
5.10
Chairman’s Closing Remarks and Close of Day Two
x your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Official Media Partners
Supported by

4. INTERACTIVE POST-CONFERENCE WORKSHOP
Wednesday 21st May 2014
Holiday Inn Regents Park Hotel, London, UK
8.30am - 12.30pm
A: How Can Success in
Analgesia be Improved?
Workshop Leaders:
Steve Harrison, Vice President, Research Biology,
Nektar Pharmaceuticals
Birgit Priest, Research Advisor, Eli Lilly
Overview of the workshop
Lack of efficacy is the root cause for
approximately half of failures both in Phase II and
Phase III. This workshop will focus on addressing the
issues that are arising and evaluating how to
improve clinical trial design to ensure success.
Steve will address Nektar’s approach to improving
success, improving the efficacy and safety of
drugs known to work in the clinic.
What approaches have the Industry taken to
address this?
• Linkage between target and disease
• Disconnect between animal and human data
(what models are truly translational?)
• Phenotypic vs. target-based screening
Key Benefits of Attending:
• Gain understanding on ways to address issues
arising in clinical trial design
• Learn how to identifying key challenges in
design when benchmarking
• Enhance the translational gap between animal
and human models
• Review phenotypic vs. target-based screening
Programme
8.30
Registration and Coffee
9.00
Introduction on identifying key
challenges in clinical trial design
with a real life scenario given as the
simulation exercise
10.30
Coffee Break
11.00
The group will discuss ways to address
key issues arising in clinical trial design
11.30
Assessing the translational gap between
animal and human models
12.30
Close of Workshop
About the workshop host
Steve Harrison is responsible for the
research biology activities at Nektar
Therapeutics and leads efforts that
identify potential new drugs to treat pain
and cancer. His team supports the
transition of these new agents into clinical testing.
Prior to joining Nektar, Steve was Senior Vice
President of Research at KAI Pharmaceuticals and
led the Discovery and Preclinical efforts for that
company, involving support for clinical
development of agents in pain, cardiovascular
disease and renal dysfunction.
Birgit Priest received her Ph. D. in Biochemistry &
Biophysics from Oregon State University in 1993.
Her thesis work on muscarinic receptors was
completed under the guidance of Dr. Michael
Schimerlik. She then trained in electrophysiology
as a post-doctoral fellow in the laboratories of Dr
Joseph Patlak (University of Vermont) and Dr John
Adelman (Vollum Institute). In 1998, Birgit joined
Merck Research Labs, where, for 13 years, she
worked on a number of voltage- and ligandgated ion channel programs. At the beginning of
2011, Birgit started a position with Eli Lilly where she
continues her work of ion channel drug discovery.
Her primary research interest has been in the role
of sodium channels in sensory functions.

5. INTERACTIVE POST-CONFERENCE WORKSHOP
Wednesday 21st May 2014
Holiday Inn Regents Park Hotel, London, UK
1.30pm - 5.30pm
B: Opportunities for
Collaborative Pain Projects
Workshop Leader:
Fiona Boissonade, Head of Neuroscience,
University of Sheffield
Overview of the workshop
In modern drug discovery the path from concept
to patient is more and more dependent on
collaborations (as opposed to the “old world”
where everything was done within big pharma
companies). Centres of excellence are formed in
large pharma companies that coordinate work
performed at contract research organisations
(CROs), academia and public institutions. Also,
centres dedicated to drug discovery outside of
the traditional private sector are starting to
emerge. Among the challenges: how to achieve
transparency between the partners (e.g.
academia and industry).
This workshop will enable Industry and Academia
to discuss the alliances which hold great benefit
specifically related to pain projects for novel
analgesics. Short Case studies from Pharma and
Academia will kick-off the discussion which will
lead to a stronger working approach for targeting
novel pain therapeutics.
Key Benefits of Attending
• Gain insight on how existing alliances are
making progress
• Discuss the enhancements to ensure
collaborations are successful
• Hear the latest case studies with strategies
on how to address benefits when making a
cooperation between Pharmaceutical
Companies and Academic Institutions
• Learn what companies and academics look
to achieve from these partnerships
Programme
1.30
Registration and Coffee
2.00
Reviewing existing alliances and
making progress to partnerships
2.30
Discussing how to enhance
collaborations to ensure they’re
successful
3.00
Afternoon Tea
3.30
Evaluating strategies on how to address
benefits when make a cooperation
between Pharmaceutical Companies
and Academic institutions
4.30
Learn what companies and academics
look to achieve from partnerships
5.30
Close of Workshop
About the workshop host
Fiona Boissonade is a dental surgeon and Professor
of Neuroscience at the University of Sheffield School
of Clinical Dentistry, where she leads the
Neuroscience Research Group. Her major research
interest is in the mechanisms of altered neuronal
excitability that occur under the pathological
conditions of nerve injury and inflammation, and
which contribute to the development of chronic
pain. Her work focuses on interdisciplinary studies
funded by RCUK, industry and research charities. A
significant portion of this research has been done at
the academic–industrial interface; collaborations
with GlaxoSmithKline, Pfizer, Eli Lilly and Renovo have
funded a wide range of pre-clinical translational
studies related to pain and nerve regeneration. She
also has a number of collaborations with other
academic researchers at the University of Sheffield
and other universities in the UK and overseas (eg
Leeds University, Karolinska Institute, Yale University).

6. PAIN THERAPEUTICS
Conference: Monday 19th and Tuesday 20th May 2014, Holiday Inn Regents Park Hotel, London, UK
Workshop: Wednesday 21st May 2014, London
4 WAYS TO REGISTER
www.pain-therapeutics.co.uk
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
EARLY BIRD □
DISCOUNT □
Book by 28th February to receive £300 off the conference price
Book by 31st March to receive £100 off the conference price
CONFERENCE PRICES
Unique Reference Number
Our Reference
LV P-104
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title:
Forename:
Surname:
Job Title:
I would like to attend: (Please tick as appropriate)
COMMERCIAL ORGANISATIONS
□ Conference and 2 Workshops
□ Conference and 1 workshop
□ Conference only
□ 2 Workshops only
□ 1 workshop only
□ Workshop A
□ Workshop B
Fee
£2697.00
£2098.00
£1499.00
£1198.00
£599.00
Total
+VAT
+VAT
+VAT
+VAT
+VAT
£3236.40
£2517.60
£1798.80
£1437.60
£718.80
+ VAT
£1198.80
PROMOTIONAL LITERATURE DISTRIBUTION
Department/Division:
□ Distribution of your company’s promotional
literature to all conference attendees
£999.00
Company/Organisation:
Email:
Company VAT Number:
The conference fee includes refreshments, lunch, conference papers and access
Address:
to the Document Portal containing all of the presentations.
LIVE STREAMING/ON DEMAND/ DOCUMENTATION
Town/City:
Post/Zip Code:
Country:
Direct Tel:
Direct Fax:
Unable to travel, but would like to watch the conference live, ask questions,
participate as if you were in the room.
Price
Total
□ Live Streaming
□ On demand
Mobile:
Switchboard:
Signature:
Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title:
£999.00 + VAT (UK) £1198.80
£599.00 + VAT (UK) £718.80
(available 24 hours after the event)
□ Access to the conference documentation
on the Document Portal
£499.00 + VAT
£499.00 (or only £300 if ordered with the Document Portal)
□ The Conference Presentations - paper copy
Forename:
£598.80
£499.00
Surname:
Email:
PAYMENT
Address (if different from above):
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-104 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
Town/City:
Post/Zip Code:
Country:
Direct Tel:
Direct Fax:
VENUE Holiday Inn, Regents Park, Carburton Street, London, W1W 5EE
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Terms and Conditions of Booking
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
of event require payment on booking. Access to the Document Portal will not be given until payment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □ we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
□ UK BACS
□ Wire Transfer
□ Cheque
□ Credit Card
Sort Code 300009, Account 00936418
Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
We can only accept Sterling cheques drawn on a UK bank.
□ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
□□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Card No:
Cardholder’s Name:
Signature:
Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live
Streaming, on Demand, Document portal and literature distribution for all UK customers and
for those EU Customers not supplying a registration number for their own country here.
______________________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk